The upcoming report from South Plains Financial (SPFI) is expected to reveal quarterly earnings of $0.77 per share, indicating an increase of 16.7% compared to the year-ago period. Analysts forecast revenues of $51.7 million, representing an increase of 6.4% year over year.The consensus EPS estimate for the quarter has been revised 2.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timefra ...

Analysts on Wall Street project that M&T Bank Corporation (MTB) will announce quarterly earnings of $4.03 per share in its forthcoming report, representing an increase of 6.3% year over year. Revenues are projected to reach $2.39 billion, increasing 3.6% from the same quarter last year.The consensus EPS estimate for the quarter has undergone a downward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial ...

In its upcoming report, Progressive (PGR) is predicted by Wall Street analysts to post quarterly earnings of $4.30 per share, reflecting an increase of 62.3% compared to the same period last year. Revenues are forecasted to be $21.52 billion, representing a year-over-year increase of 17.9%.The consensus EPS estimate for the quarter has been revised 1.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates d ...

Rhythm Pharmaceuticals, Inc. (RYTM) shares rallied 36.6% in the last trading session to close at $89. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.3% loss over the past four weeks.The stock rallied after the company announced positive top-line data from a phase II study evaluating its investigational oral melanocortin-4 receptor (MC4R) agonist, bivamelagon, in patients with acquired hypothalamic obesity. ...

Vir Biotechnology, Inc. (VIR) shares soared 11.9% in the last trading session to close at $5.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.2% loss over the past four weeks.The sudden rise in the stock price can be attributed to the positive investor mindset regarding the potential of Vir Biotechnology’s only late-stage pipeline candidate, tobevibart. It is being developed in combination with Alnylam’s elebsiran, in a regi ...

MiMedx (MDXG) shares soared 8% in the last trading session to close at $7. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.5% gain over the past four weeks.The sudden rise in price can be attributed to growing investors’ optimism related to the company’s efforts to develop and provide a leading portfolio of products for applications in the wound care, burn and surgical sectors of healthcare.This developer of biomaterials made f ...

Company Overview - Granite Ridge Resources, Inc. (GRNT) shares increased by 6.7% to close at $6.41, supported by higher trading volume compared to normal sessions [1] - The company is positioned to benefit from rising oil prices due to geopolitical tensions, particularly the conflict between Israel and Iran, which has led to a 13% increase in Brent crude and a 10% increase in West Texas Intermediate (WTI) [2] Financial Performance - Granite Ridge is expected to report quarterly earnings of $0.17 per share, reflecting a year-over-year increase of 30.8%, with revenues projected at $111 million, up 22.5% from the previous year [3] - The consensus EPS estimate for Granite Ridge has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Market Position - The company operates as a non-operated oil and natural gas exploration and production entity with a diverse portfolio across major U.S. basins, which enhances its operational flexibility and attractiveness in a volatile market [2] - Granite Ridge holds a Zacks Rank of 3 (Hold), indicating a neutral outlook in the current market context [5]

Core Viewpoint - Guidewire Software (GWRE) is expected to report significant growth in earnings and revenues for the upcoming quarter, with analysts projecting earnings of $0.46 per share and revenues of $285.72 million, reflecting year-over-year increases of 76.9% and 18.7% respectively [1] Earnings Projections - Analysts predict quarterly earnings of $0.46 per share, marking a 76.9% increase from the same period last year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, indicating stability in analysts' projections [1] Revenue Estimates - Total revenues are forecasted to be $285.72 million, representing an 18.7% year-over-year increase [1] - 'Revenue- Subscription and support' is expected to reach $178.14 million, a 29.1% increase from the prior year [4] - 'Subscription Revenue' is projected at $162.74 million, indicating a 35.1% increase from the previous year [4] - 'Revenues- License' is estimated to be $55.33 million, reflecting a slight decrease of 1.6% from the prior year [4] Service and Support Revenue - 'Revenues- Services' is projected to be $52.00 million, showing an 11.8% year-over-year increase [5] - 'Support Revenue' is expected to decline to $15.41 million, a decrease of 12.2% from the previous year [5] - 'Term License Revenue' is estimated at $54.48 million, indicating a 1% decrease year-over-year [5] Annual Recurring Revenue - The consensus estimate for 'Annual recurring revenue' stands at $944.40 million, up from $828 million a year ago [6] Gross Profit Estimates - 'Gross profit- Subscription and support' is expected to be $120.51 million, compared to $86.79 million reported in the same quarter last year [6] - 'Gross profit- License' is projected to reach $54.87 million, slightly down from $55.37 million reported in the same quarter last year [7] Stock Performance - Guidewire Software shares have increased by 1.9% over the past month, while the Zacks S&P 500 composite has risen by 6.7% [7] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [7]

Core Insights - Wall Street analysts forecast Synopsys (SNPS) to report quarterly earnings of $3.39 per share, reflecting a year-over-year increase of 13% [1] - Anticipated revenues for Synopsys are projected to be $1.6 billion, indicating a 10.1% increase compared to the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, suggesting a reassessment of projections by covering analysts [1] Revenue Estimates - Revenue from Maintenance and Service is expected to reach $279.24 million, showing a year-over-year change of +1% [3] - Total Products Revenue is estimated at $1.32 billion, indicating a +12.3% change from the prior-year quarter [4] - Revenue by segment for Design IP is projected to be $443.37 million, reflecting a +10.9% change from the year-ago quarter [4] - Revenue by segment for Design Automation is anticipated to reach $1.16 billion, indicating a +9.9% change from the prior-year quarter [4] - Upfront Products revenue is forecasted at $415.15 million, suggesting a +4.7% year-over-year change [5] - Time-based Products revenue is expected to come in at $904.12 million, reflecting a +15.7% change from the year-ago quarter [5] Stock Performance - Synopsys shares have increased by +14.7% in the past month, outperforming the Zacks S&P 500 composite, which has moved up by +10.7% [6] - The company holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [6]

Wall Street analysts forecast that Salesforce.com (CRM) will report quarterly earnings of $2.54 per share in its upcoming release, pointing to a year-over-year increase of 4.1%. It is anticipated that revenues will amount to $9.74 billion, exhibiting an increase of 6.6% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Befor ...